Notice of AGM
Solvonis Therapeutics plc has announced the notice of its 2026 Annual General Meeting, which will be held on June 19, 2026, at 9:00 am at its registered office. The company, which develops small-molecule therapeutics for central nervous system disorders, has posted the notice and proxy form to shareholders and submitted them to the National Storage Mechanism. This announcement is procedural and does not contain new financial performance data or strategic updates that would directly impact the stock share price.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, is pleased to announce that the notice of the Company's 2026 AGM and proxy form have today been posted to shareholders and can be found on the Company's website at https://solvonis.com/investor-relations/shareholder-circulars.
The Annual General Meeting will take place at 9.00am on 19 June 2026 at the Company's registered office being, 25 Eccleston Place, London SW1W 9NF.
In compliance with Listing Rule 9.6.1R, the notice of AGM and proxy form have today been submitted to the National Storage Mechanism and will shortly be available at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
| solvonis.com | X (Twitter) |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.